The FDA has approved Novartis' Exelon for Parkinson's patients with mild to moderate dementia. This is the first approval for a drug that treats this condition. Exelon has also been approved for Alzheimer's and was approved for Parkinson's in Europe last March. The approval was based on data from a pivotal study involving 541 patients which demonstrated significant improvements in overall functioning with less deterioration in daily functions.
- here's the AFX report on Exelon